Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
The U.S. Food and Drug Administration has approved a three-drug regimen to treat complicated urinary tract infections and complicated intra-abdominal infections, both of which can be especially problematic for people living with HIV.
Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
For people who used cocaine after being cured of HCV, the health of their kidneys declined at a relatively rapid pace.
Having HIV infection raised the chances of impaired kidney function by three standard measures in a Dutch comparison of aging adults living with versus without HIV.
Switching from a suppressive five-drug regimen to Genvoya and Prezista proved virologically noninferior to maintaining the initial regimen at 24 weeks and virologically superior at 48 weeks.
Hepatitis C independently raised the risk of kidney disease and osteoporosis or fracture in an analysis of 5,000 people with HIV.
Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.